Neil Kumar

CEO Neil Kumar sells 80,000 BBIO shares for $5.4M under pre-arranged 10b5-1 plan on 2026-06-04/05

Neil Kumar, Chief Executive Officer of BridgeBio Pharma, executed 14 separate sales totaling 80,000 shares for $5,413,288.79 at a blended average price of $67.67 across June 4–5, 2026. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning the sales were scheduled in advance and not discretionary decisions. Kumar retains 4,318,447 shares post-transaction, representing a -1.8% reduction in his holdings. The company is unprofitable with net income of $-166,555,000.00 on quarterly revenue of $194,515,000.00, though annual revenue growth stands at +126.3%. The stock currently trades at $67.37, -20.7% from its 52-week high of $84.94 and -9.4% over the past 90 days, placing the transaction near recent lows within the year's range.

CEO Neil Kumar sold 26,103 shares for $1.8M (blended avg $69.44) on 2026-05-21 under pre-arranged 10b5-1 plan.

CEO Neil Kumar executed five separate sales totaling 26,103 shares for $1,812,521.76 on a single trading date, reducing his holdings by 9.7% to 243,327 shares. This transaction was scheduled under a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning it was not a discretionary decision but part of a predetermined execution schedule. The stock currently trades at $67.73, down 20.3% from its 52-week high of $84.94 and off 7.6% over the past 30 days, though it has gained 1.8% over 90 days. BridgeBio remains unprofitable with a $-166.6M net loss in the most recent quarter against $194.5M in revenue, though the company has achieved 126.3% annual revenue growth. Since this sale was scheduled rather than discretionary, it does not signal conviction or concern about near-term valuation; investors should focus instead on the company's fundamental trajectory as a high-growth but currently loss-making pharma organization.

BridgeBio CEO Kumar Neil sells ~$5.4M of stock (80,000 shares) via 12 transactions; his 126th-137th open-market sale in 3 years, no purchases.

Kumar Neil, BridgeBio's CEO, sold approximately 80,000 shares over two trading days in early May totaling roughly $5.4M—his 126th through 137th open-market sale in the past three years, with zero open-market purchases in that period. The stock currently trades roughly 15% below its 52-week high and has declined modestly over the past three months, creating a backdrop where the CEO is choosing to reduce his position. His five prior sales at BridgeBio were all followed by stock declines, demonstrating consistent timing accuracy on those exits. The company is unprofitable on an annual basis, though quarterly results show a modest loss, alongside strong revenue growth that has more than doubled year-over-year, suggesting a cash-intensive growth business. The sale itself is not unusual for a pharmaceutical company burning cash, but the three-year pattern of continuous selling and complete absence of any open-market purchases is noteworthy for someone running the company—it reflects a persistent divestiture posture rather than conviction in the business or willingness to put personal capital at risk.

CEO Kumar Neil sold 80,000 shares (1.8% of holdings) for $5,968,780.09 across 8 transactions on Apr 9-10

Kumar Neil, Chief Executive Officer of BridgeBio Pharma, executed 8 separate sales totaling 80,000 shares for $5,968,780.09 at a blended average price of $74.61, reducing his holdings from 4.48M to 4.40M shares. The stock currently trades at $77.87, 2.6% below its 52-week high, and has risen 12.2% over the past 30 days. His prior 5 trades at BBIO (all on 2026-03-12 and 2026-03-13) showed 30-day returns of +6.3% to +9.1%, indicating his recent sales have been followed by near-term price strength rather than subsequent declines. BridgeBio remains unprofitable with a net loss of $-184,937,000 in its latest fiscal year, though revenue growth has accelerated to +126.3% annually. The substantial dollar volume and timing across two calendar days warrants examination of broader context to assess whether this represents opportunistic liquidation or part of a planned program.

CEO Kumar Neil sold 80,000 shares (80.0K shares) for $5,501,068.07 ($5.5M) on 2026-03-12 to 2026-03-13; retains 4,438,447 shares (4.44M shares) post-transaction.

Kumar Neil, CEO of BridgeBio Pharma, executed 10 separate sales totaling 80,000 shares (80.0K shares) for $5,501,068.07 ($5.5M) over two trading days at prices ranging from $68.36 to $70.15, with a blended average of $68.76. The sale represents a -1.8% reduction in his prior holdings of 4,518,447 shares (4.52M shares). Context shows the company is unprofitable (full-year net income was negative) despite strong annual revenue growth of +126.3%, and the current stock price of $71.03 is -11.1% from the 52-week high. His cross-ticker track record across 20 prior sells shows an average 30-day return of -6.5%, though his same-ticker history at BBIO over 5 prior trades shows limited measurable outcomes, with recent February sales posting mixed 30-day returns of -1.8% and -4.5%. The magnitude and timing of this multi-day liquidation warrant examination of underlying catalysts and broader market positioning.

CEO Kumar Neil sells 28,053 shares (28.1K) for $2.0M at $71.39 blended avg, stock now $67.91

CEO Kumar Neil executed 3 separate sales totaling 28,053 shares for $2,002,717.48 on 2026-02-19 at prices ranging from $71.03 to $72.80, reducing his holdings by 10.7%. The stock has declined 15.0% from its 52-week high of $79.91 and is currently trading at $67.91, below the blended sale price of $71.39. BridgeBio is unprofitable with annual net income of $-184,937,000.00 despite explosive revenue growth of 2285.3% year-over-year; the company reported quarterly revenue of $120,700,000.00 but remains deeply loss-making. The timing of this sale eight days after five consecutive sell transactions on 2026-02-11 occurs against a backdrop of deteriorating stock momentum (30-day decline of 12.8%) and a fundamentally unprofitable business in a period of significant valuation pressure.

CEO Kumar Neil sells 80,000 shares (80.0K) for $5,748,666.24 in 12 transactions over 2 days at BBIO

Kumar Neil, CEO of BridgeBio Pharma, executed 12 separate sales totaling 80,000 shares for $5,748,666.24 at a blended average price of $71.86 over February 10–11, 2026, reducing his holdings by 1.8% to 4,478,447 shares. The current stock price of $76.06 is 4.8% below the 52-week high of $79.91, suggesting the market remains near elevated levels. Of notable concern: Kumar Neil's prior 5 sales at BBIO (all on 2026-01-09) showed consistently negative 30-day returns ranging from -10.2% to -13.0%, indicating a pattern of selling before near-term declines at this specific ticker. His cross-ticker track record across 20 prior sells averaged a -5.5% 30-day return, further suggesting a tendency to sell into weakness or ahead of softness. The company remains unprofitable with a net income of $-184,937,000.00 on revenue of $120,700,000.00, though annual revenue growth of 2285.3% signals a rapidly scaling business; however, the magnitude and consistency of losses warrant attention to cash burn and path to profitability.

CEO Kumar Neil sells 80,000 BBIO shares for $6.0M over two days; retains 4.52M shares post-sale.

Kumar Neil, Chief Executive Officer of BridgeBio Pharma, executed 14 separate sales totaling 80,000 shares for $6,043,168.21 across January 8–9, 2026, at an average price of $75.54. This represents a 1.7% reduction from pre-transaction holdings of 4.60M shares, leaving him with 4.52M shares—a substantial continued position. The company is unprofitable with net income of $-184,937,000.00 over its most recent full fiscal year, though it has experienced explosive annual revenue growth of +2285.3%. The sale occurred when the stock was near its 52-week high of $78.24 (current price $76.84 is -1.8% from that high), and the stock has delivered a strong 90-day return of +36.0% heading into this transaction. Against the backdrop of a loss-making but rapidly scaling revenue base, a large-dollar insider sale by the CEO at elevated valuation levels merits attention to understand the commercial context and capital allocation priorities.

CEO Kumar Neil sold 30,011 shares at blended avg $74.64 on 2025-12-15, reducing stake to 228,776 shares

Kumar Neil, Chief Executive Officer of BridgeBio Pharma, executed 2 separate sales totaling 30,011 shares for $2,239,902.15 on 2025-12-15, reducing his holdings by 11.6% to 228,776 shares. The sales occurred at a blended average price of $74.64, which is at the current price of $75.69 (the stock is +0.0% from its 52-week high of $75.69 and up 14.0% over 30 days and 47.9% over 90 days). This sale follows four other sales by the same insider at BBIO on 2025-12-05 and 2025-12-04, indicating a pattern of recent consecutive dispositions. The underlying company is unprofitable (full-year net income was negative) despite strong recent revenue growth of 2285.3% year-over-year, and faces a challenging path to profitability with a $14.6B market cap. While the CEO's cross-ticker track record shows positive average 30-day returns of 18.6% after sells, his recent BBIO-specific trades are not yet measurable at the 90-day mark, making this clustering of executive dispositions noteworthy for monitoring.

CEO Kumar Neil sold 80,000 shares ($5.9M) across 10 transactions at $73.05–$74.80; retains 4,558,447 shares.

Kumar Neil, Chief Executive Officer of BridgeBio Pharma, executed 10 separate sales totaling 80,000 shares for $5,908,475.90 over two days (2025-12-04 and 2025-12-05), at a blended average price of $73.86 and current price $74.24, resulting in a -0.7% move from the 52-week high of $74.76. The stock has appreciated +20.1% over 30 days and +38.8% over 90 days, and the company reported annual revenue growth of +2285.3% while remaining unprofitable with a net income of $-184,937,000.00 in its most recent full fiscal year. Neil retains 4,558,447 shares post-transaction, a reduction of 1.7% from his pre-transaction holdings; his cross-ticker track record of 20 prior sells averaged a +16.1% return within 30 days, suggesting his past timing has not typically caught downturns. The timing pattern across his same-ticker history at BBIO (5 prior trades, all sells) remains mixed at the measurable 30-day mark (+19.0% and +20.5%), with no 90-day outcomes yet established.